Biotech Stocks Reviews
- Market Overreacts to Amarin’s 3 Month Delay
Fri, Aug 9
What Happened?Amarin (AMRN) was down 20% in aftermarket trading yesterday upon announcing that the FDA · more » - Expectations for Adverum’s WetAMD Phase 1 Data in September
Sun, Jul 28
ADVM will present Phase 1 data in Wet AMD this September We set expectations for September data by · more » - Key Takeaways From Bellus’ Chronic Cough KOL Call
Tue, Jul 16
Bellus hosted their Chronic Cough KOL meeting this morning. It was paneled by: Jacky Smith: lead · more » - Merck’s Plan of a P2X3 Pipeline Lifts Bellus
Sat, Jun 22
Last week, Bellus (BLUSF) rallied from $1.50 range to over $2.00, touching a high of $2.31. This all · more » - Late 2019 Data Could Position Gene Therapy Company As Leading Candidate in Wet AMD
Mon, Jun 3
Adverum (ADVM) has rallied year to date from $3.50 to $10/share as the market is picking up on the gene · more » - Acer’s Clinically Relevant Data Could Be Enough For Desperate Patient Population
Thu, May 2
Acer Therapeutics (ACER) has a PDUFA date on June 25, 2019 for the treatment of vascular Ehlers-Danlos · more » - With Completion of Spring Bank’s (SBPH) ACHIEVE, All Eyes on Gilead’s Combination Data
Fri, Apr 12
Spring Bank (SBPH) presented data for their Phase 2 ACHIEVE trial at EASL conference today, including · more » - Aldeyra’s Allergic Conjunctivitis Data Positions Candidate Well in Dry Eye Disease
Tue, Mar 26
This morning Aldeyra released topline data for their Phase 3 candidate reproxalap in allergic · more » - Market Overlooking Eventful Upcoming 12 Months for Spring Bank (SBPH)
Fri, Mar 15
Spring Bank provided a business update earlier this week to discuss 2019 development plant for their · more »